サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1663455

自己投与型医薬品の世界市場：種類別・適応症別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)

Self-administered Drugs Market, By Type, By Indication, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日
ページ情報
英文 284 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.00円
自己投与型医薬品の世界市場：種類別・適応症別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)
出版日: 2025年02月04日
発行: AnalystView Market Insights
ページ情報: 英文 284 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

自己投与型医薬品の市場規模は2024年に885億1,460万米ドルとなり、2025年から2032年にかけてCAGR 7.10%で拡大

自己投与型医薬品の市場力学

慢性疾患の増加

自己投与型医薬品市場を推進している主な要因の1つは、糖尿病、高血圧、自己免疫疾患などの慢性疾患の増加です。より多くの患者が継続的な薬を必要としているため、自分で投与する形の医薬品はますます普及しています。患者が自分のスケジュールに合わせて薬を服用できる自由と利便性を提供することで、これらの医薬品は医療機関の負担を軽減するだけでなく、患者の生活の質を向上させます。さらに、より健康志向の強い社会へと文化が変化しているため、個人の医療に対する積極性や知識も高まっており、自己投与型医薬品に対する需要や受容性が高まっています。

自己投与型医薬品市場：主な考察

弊社のリサーチアナリストの分析によると、世界市場は予測期間 (2025-2032年) に約7.10%のCAGRで毎年成長すると予測されています。

市場セグメンテーションに基づくと、2024年には注入剤カテゴリーが最大の市場シェアを示すと予測されます。

適応症別では、疼痛管理が2024年に主要セグメントとなる

地域別では、北米が2024年に収益をもたらす主要市場です。

自己投与型医薬品市場：セグメンテーション分析

世界の自己投与型医薬品市場は、種類、適応症、地域別に区分されます。

種類別では、注入剤、経皮吸収剤、吸入剤に分類されます。2024年、市場は注入剤カテゴリーが支配的でした。生物学的製剤やバイオシミラーの普及に伴い、注射式の自己投与型医薬品の人気が高まっています。これらの医薬品は、正確な投与や投薬が頻繁に必要とされますが、自動注射器やプレフィルドシリンジの新たな開発により、家庭での使用が容易になりました。関節リウマチ、多発性硬化症、さまざまなホルモン異常などの治療では、注射薬を使用することが多く、患者は自己注射の手軽さにますます興味を持つようになっています。より患者に優しいデバイスや痛みの少ない市場開拓技術が開発され続けるにつれ、注入剤市場は急速に拡大すると予測されます。

適応症に基づき、市場は糖尿病、心血管、疼痛管理、ホルモン補充療法、骨粗鬆症、その他に分けられます。2024年には、疼痛管理カテゴリーが圧倒的な市場シェアを占めています。自己投与型医薬品の市場には、疼痛管理が重要な応用分野として含まれており、急性疼痛と慢性疼痛の両方を治療するための、患者に優しく効率的な方法に対する需要の高まりを示しています。外用クリーム、経口薬、経皮パッチなどの自己投与型鎮痛薬は、患者が必要に応じて治療方針を変更できるため、手軽さと適応性の点で大きなメリットがあります。神経障害性疼痛や関節炎を含む疾病の有病率の増加により、自己管理による疼痛管理の必要性が高まることが予想され、その開発が薬剤の処方や送達システムの助けとなると思われます。

自己投与型医薬品市場：地域別分析

2024年現在、自己投与型医薬品の世界市場では北米が圧倒的な地位を占めています。糖尿病、がん、骨疾患の有病率の上昇と、これらの症状に対処する患者の間で自己投与型医薬品に対する強い需要が、市場拡大の主な要因となっています。さらに、この地域の経済大国の政府は、保険を提供することにより、様々な自己投与型医薬品の採用を支援しています。USFDAによる医薬品認可の増加は、新規市場参入企業の事業拡大に道を開く。例えば、USFDAは2020年6月、イーライリリー・アンド・カンパニーに対し、1型および2型糖尿病の成人の血糖コントロールを改善することを目的とした新規速効型インスリン製剤「リュミジェブ」の追加承認を与えました。インスリンリスプロの革新的なバージョンがリュムジェブと呼ばれています。この開発企業は、A1C値を下げ、インスリンを速やかに血流に吸収させるソリューションを開発しました。さらに、食後の糖尿病患者の血糖値上昇を抑制します。処方箋がなくても、この新しい適応症により、症状の有無にかかわらず誰でも検査が受けられるようになります。

しかし、予測期間を通じて、アジア太平洋地域のCAGRが最も速いと予想されています。慢性疾患の蔓延、医療費の増大、医療サービスへのアクセスの容易さなどが、簡単でリーズナブルな価格の治療オプションに対する同地域のニーズの高まりにつながっています。高齢化により慢性疾患管理への関心が高まり、自己管理型医薬品の使用に拍車がかかっています。さらに、医療インフラへの投資や医療ツーリズム産業の拡大により、小売薬局はオンラインでの医薬品流通を拡大するよう促されています。

自己投与型医薬品市場：競合情勢

自己投与型医薬品の世界市場における主要企業としては、オムニケア、SFKコーポレーション、ジョンソン・エンド・ジョンソン、カーディナル・ヘルス、マッケソン・コーポレーションなどが挙げられます。市場での競争力を維持するために、提携、共同研究、地域拡大、M&A、新薬開発など、いくつかの戦術を実施することで、市場参入企業もその成長に大きく貢献しています。さらに、患者の服薬アドヒアランスを高め、最先端のドラッグデリバリー方法を開発するため、この分野の企業は研究開発に多額の投資を行っています。患者や医療専門家の需要の変化に対応するため、新商品や新技術のリリースが続いており、市場の競争が激化しています。例えば、アボット・ラボラトリーズは2021年9月、医療機器メーカーのウォーク・バスキュラーLLCを買収したと発表しました。アボット社の末梢血管ポートフォリオを拡大し、血管内治療ソリューションを進歩させることで、この買収は患者ケアを強化します。

最近の動向

2024年2月：FDAはノバルティスにXolair (R) (オマリズマブ) の導入許可を与えました。この自己注射薬は、IgE介在性の食物アレルギーを持つ成人および小児のアナフィラキシーやその他のアレルギー反応の予防に役立ちます。

目次

第1章 自己投与型医薬品市場の概要

  • 調査範囲
  • 市場推定期間

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 自己投与型医薬品の主な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 自己投与型医薬品市場：産業分析

  • PEST分析
  • ポーターのファイブフォース分析
  • 市場成長の見通し：マッピング
  • 規制体制の分析

第5章 自己投与型医薬品市場：COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19以後の影響分析

第6章 自己投与型医薬品の市場情勢

  • 自己投与型医薬品の市場シェア分析 (2024年)
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 自己投与型医薬品市場：種類別

  • 概要
    • セグメント別シェア分析：種類別
    • 注入剤
    • 経皮吸収材
    • 吸入剤

第8章 自己投与型医薬品市場：適応症別

  • 概要
    • セグメント別シェア分析：適応症別
    • 糖尿病
    • 心血管
    • 疼痛管理
    • ホルモン補充療法
    • 骨粗鬆症
    • その他

第9章 自己投与型医薬品市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋 (APAC)
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 韓国
    • 日本
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第10章 主要ベンダー分析：自己投与型医薬品業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Omnicare
    • SFK Corporation
    • Johnson &Johnson
    • Cardinal Health
    • McKesson Corporation
    • Wal-Mart Stores Inc
    • Express Scripts Holding Company
    • CVS Health
    • Walgreens Boots Alliance
    • Rite Aid Corporation
    • Others

第11章 AnalystViewの全方位的分析

目次
Product Code: ANV4610

REPORT HIGHLIGHT

Self-administered Drugs Market size was valued at US$ 88,514.6 Million in 2024, expanding at a CAGR of 7.10% from 2025 to 2032.

Self-administered drugs are those that patients administer to themselves. Both implanted and non-implantable infusion pumps that come into contact with the skin's surface can be used to provide these medications. Self-administered drugs also include over-the-counter, oral, and topical medicines. Patients who lead active lives are looking for medications that will not only save them time but also allow them to stay out of hospitals completely (apart from emergencies). The market for self-administered drugs is expanding as a result of this trend. Policies for reimbursement will also accelerate market expansion. Furthermore, the self-administered drugs market is expected to expand because of factors such as the migration of patient populations to developed nations and the high expense of healthcare, which incentivizes patients to use self-administered drugs.

Self-administered Drugs Market- Market Dynamics

Increase in chronic illnesses

One major reason propelling the self-administered drugs market is the increase in chronic illnesses like diabetes, hypertension, and autoimmune disorders. Drugs that are self-administered are becoming more and more popular as more patients need ongoing medicine. By giving patients the freedom and convenience to take their medications on their schedules, these pharmaceuticals not only lessen the strain on medical institutions but also improve patients' quality of life. Furthermore, individuals are becoming more proactive and knowledgeable about their healthcare due to the cultural shift towards a more health-conscious society, which is raising the demand for and acceptance of self-administered choices.

Self-administered Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.10% over the forecast period (2025-2032)

Based on type segmentation, the Injectable Drugs category was predicted to show maximum market share in the year 2024

Based on indication segmentation, pain management was the leading segment in 2024

On the basis of region, North America was the leading revenue generator in 2024

Self-administered Drugs Market- Segmentation Analysis:

The Global Self-administered Drugs Market is segmented on the basis of Type, Indication, and Region.

On the basis of type, the market is segregated into Injectable Drugs, Transdermal Drugs, and Inhaled Drugs. In 2024, the market was dominated by the Injectable Drugs category. With the popularity of biologics and biosimilars, injectable self-administered drugs are becoming more and more popular. These medications frequently need to be administered and dosed precisely, which new developments in auto-injectors and pre-filled syringes have made easier to use at home. Treatments for diseases like rheumatoid arthritis, multiple sclerosis, and different hormonal abnormalities frequently call for injectables, and patients are becoming more and more interested in the ease of self-administration. As more patient-friendly devices and less painful delivery technologies continue to be developed, the injectable market is predicted to increase rapidly.

Based on indication, the market is divided into Diabetes, Cardiovascular, Pain Management, Hormone Replacement, Osteoporosis, and Others. In 2024, the pain management category held a dominant market share. The market for self-administered drugs includes pain management as a crucial application area, demonstrating the rising demand for patient-friendly and efficient ways to treat both acute and chronic pain. Self-administered analgesics, such as topical creams, oral drugs, and transdermal patches, provide substantial benefits in terms of ease and adaptability, enabling patients to modify their course of treatment as necessary. It is anticipated that the need for self-managed pain management choices will increase due to the growing prevalence of diseases, including neuropathic pain and arthritis, which developments will aid in medication formulations and delivery systems.

Self-administered Drugs Market- Geographical Insights

In 2024, North America held a dominant position in the global market for Self-administered Drugs. The rising prevalence of diabetes, cancer, and bone ailments, as well as the strong demand for self-administered drugs among patients coping with these conditions, are the main drivers of the expansion. Additionally, the government of the biggest economies in the region supports the adoption of various self-administered drugs by offering insurance. Increased USFDA medicine approvals pave the way for new market participants to expand. For instance, the USFDA granted additional clearances to Eli Lilly and Company in June 2020 for their novel rapid-acting insulin, "Lyumjev," which is intended to help adults with type 1 and 2 diabetes improve their glycemic control. An innovative version of insulin lispro is called Lyumjev. The business developed a solution to lower A1C levels and quickly absorb insulin into the bloodstream. Additionally, it regulates elevated blood sugar levels in diabetic persons after meals. Without a prescription, this new indication makes the test available to anybody with or without symptoms.

However, throughout the projected period, the Asia-Pacific region is anticipated to see the fastest CAGR. The prevalence of chronic illnesses, growing healthcare expenses, and easier access to healthcare services are all contributing to the region's growing need for easy and reasonably priced treatment options. The ageing population has increased attention to chronic condition management, which has fueled the use of self-administered drugs. Additionally, retail pharmacies are being encouraged to expand their online drug distribution due to the healthcare infrastructure investments and the expanding medical tourism industry.

Self-administered Drugs Market- Competitive Landscape:

Among the leading companies in the global market for self-administered drugs are Omnicare, SFK Corporation, Johnson & Johnson, Cardinal Health, McKesson Corporation, and others. By implementing several tactics, including partnerships, collaborations, regional expansion, mergers and acquisitions, and new drug development, to remain competitive in the market, the market's participants are also making a substantial contribution to its growth. Furthermore, to increase patient adherence and develop cutting-edge drug delivery methods, businesses in this sector are making significant investments in research and development. The ongoing release of new goods and technology to meet the changing demands of patients and healthcare professionals intensifies the market's competition. For instance, in September 2021, Abbott Laboratories declared that it had acquired Walk Vascular LLC, a manufacturer of medical devices. By expanding Abbott's peripheral vascular portfolio and advancing endovascular therapeutic solutions, this acquisition will enhance patient care.

Recent Development

February 2024: the FDA has given Novartis permission to introduce Xolair(R) (omalizumab). This self-injectable drug can help prevent anaphylaxis and other allergic responses in adults and children with IgE-mediated food allergies.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SELF-ADMINISTERED DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Omnicare
  • SFK Corporation
  • Johnson & Johnson
  • Cardinal Health
  • McKesson Corporation
  • Wal-Mart Stores Inc
  • Express Scripts Holding Company
  • CVS Health
  • Walgreens Boots Alliance
  • Rite Aid Corporation
  • Others

GLOBAL SELF-ADMINISTERED DRUGS MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Injectable Drugs
  • Transdermal Drugs
  • Inhaled Drugs

GLOBAL SELF-ADMINISTERED DRUGS MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Diabetes
  • Cardiovascular
  • Pain Management
  • Hormone Replacement
  • Osteoporosis
  • Others

GLOBAL SELF-ADMINISTERED DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Self-administered Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Self-administered Drugs Market Snippet by Type
    • 2.1.2. Self-administered Drugs Market Snippet by Indication
    • 2.1.3. Self-administered Drugs Market Snippet by Country
    • 2.1.4. Self-administered Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Self-administered Drugs Key Market Trends

  • 3.1. Self-administered Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Self-administered Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Self-administered Drugs Market Opportunities
  • 3.4. Self-administered Drugs Market Future Trends

4. Self-administered Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Self-administered Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Self-administered Drugs Market Landscape

  • 6.1. Self-administered Drugs Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Self-administered Drugs Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
    • 7.1.2. Injectable Drugs
    • 7.1.3. Transdermal Drugs
    • 7.1.4. Inhaled Drugs

8. Self-administered Drugs Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
    • 8.1.2. Diabetes
    • 8.1.3. Cardiovascular
    • 8.1.4. Pain Management
    • 8.1.5. Hormone Replacement
    • 8.1.6. Osteoporosis
    • 8.1.7. Others

9. Self-administered Drugs Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Self-administered Drugs Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Self-administered Drugs Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.7. France
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.7.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.3.7.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.8. Italy
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.8.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.3.8.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.9. Spain
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.10. United Kingdom
      • 9.3.10.1. Overview
      • 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.10.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.3.10.4. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.11. Russia
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.11.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.3.11.3. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.12. Netherlands
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.12.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.3.12.3. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.13. Sweden
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.13.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.3.13.3. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.14. Poland
      • 9.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.14.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.3.14.3. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.3.15. Rest of Europe
      • 9.3.15.1. Overview
      • 9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.3.15.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Self-administered Drugs Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.8. South Korea
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.8.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.4.8.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.9. Japan
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.4.9.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Self-administered Drugs Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Self-administered Drugs Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Self-administered Drugs Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Omnicare
    • 10.2.2. SFK Corporation
    • 10.2.3. Johnson & Johnson
    • 10.2.4. Cardinal Health
    • 10.2.5. McKesson Corporation
    • 10.2.6. Wal-Mart Stores Inc
    • 10.2.7. Express Scripts Holding Company
    • 10.2.8. CVS Health
    • 10.2.9. Walgreens Boots Alliance
    • 10.2.10. Rite Aid Corporation
    • 10.2.11. Others

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us